Cost-Effectiveness of Adding Cetuximab to Platinum-Based Chemotherapy for First-Line Treatment of Recurrent or Metastatic Head and Neck Cancer

• Malek B. Hannouf,

  Affiliation Department of Epidemiology and Biostatistics, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ontario, Canada

  ⨯
• Chander Sehgal,

  Affiliation Richard Ivey School of Business, University of Western Ontario, London, Ontario, Canada

  ⨯
• Jeffrey Q. Cao,

  Affiliations Richard Ivey School of Business, University of Western Ontario, London, Ontario, Canada, Department of Radiation Oncology, London Regional Cancer Program, London Health Sciences Centre, London, Ontario, Canada

  ⨯
• Joseph D. Mocanu,

  Affiliation Richard Ivey School of Business, University of Western Ontario, London, Ontario, Canada

  ⨯
• Eric Winquist,

  Affiliation Department of Oncology, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ontario, Canada

  ⨯
• Gregory S. Zaric

  * E-mail: gzaric@ivey.uwo.ca

  Affiliations Department of Epidemiology and Biostatistics, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ontario, Canada, Richard Ivey School of Business, University of Western Ontario, London, Ontario, Canada

  ⨯